November 21, 2018 | News
Intract Pharma’s Soteria® technology was recently profiled on Europe’s leading biotech news website, Labiotech.eu. The article comments on the potential benefit of the Soteria® technology, highlighting that oral versions of existing antibody therapies “could make the treatments easier for patients and increase compliance.” Also discussed is the £1.4m grant awarded to Intract by Innovate UK to develop a scalable manufacturing process for an oral antibody product using Soteria®.
With over 100,000 monthly visitors to the website, Labiotech.eu covers the medical, industrial and food biotech sectors over a range of different platforms.
You can find the article here:
You can also find Intract on Labiotech’s map of European Biotech companies here:
Copyright © 2018 Intract Pharma
Website Design by Creative Brand Design